ReP USP - Resultado da busca

Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Fonte: Jacc-heart failure. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 13 jun. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial (2022)
Berg, David D.; Docherty, Kieran F.; Sattar, Naveed; Jarolim, Petr; Welsh, Paul; Jhund, Pardeep S.; Anand, Inder S.; Chopra, Vijay; Boer, Rudolf A. de; Kosiborod, Mikhail N.; Nicolau, Jose Carlos
Fonte: Circulation. Nome do evento: Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, VENTRÍCULO CARDÍACO, MODELOS DE RISCOS PROPORCIONAIS, IDOSOS, ENSAIO CLÍNICO, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERG, David D. et al. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, v. 145, n. 3, p. 158-169, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.057852. Acesso em: 13 jun. 2024.
APA
Berg, D. D., Docherty, K. F., Sattar, N., Jarolim, P., Welsh, P., Jhund, P. S., et al. (2022). Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 145( 3), 158-169. doi:10.1161/CIRCULATIONAHA.121.057852
NLM
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Vancouver
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
Furtado, Remo H. M.; Raz, Itamar; Goodrich, Erica L.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; Mcguire, Darren K.; Wilding, John P. H.; Aylward, Philip; Dalby, Anthony J.; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: HIPERTENSÃO, INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS, RESULTADO DE TRATAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 13 jun. 2024.
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Artigo de periodico
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF (2022)
Butt, Jawad H.; Docherty, Kieran F.; Jhund, Pardeep S.; Boer, Rudolf A.; Bohm, Michael; Desai, Akshay S.; Howlett, Jonathan G.; Inzucchi, Silvio E.; Kosiborod, Mikhail N.; Martinez, Felipe A.; Nicolau, Jose Carlos
Fonte: European journal of heart failure. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, FIBRILAÇÃO ATRIAL, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H. et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, v. 24, n. 3, p. 513-525, 2022Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2381. Acesso em: 13 jun. 2024.
APA
Butt, J. H., Docherty, K. F., Jhund, P. S., Boer, R. A., Bohm, M., Desai, A. S., et al. (2022). Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, 24( 3), 513-525. doi:10.1002/ejhf.2381
NLM
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.2381
Vancouver
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.2381
Artigo de periodico
The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study (2021)
Jankowska, Ewa A; Kirwan, Bridget-Anne; Kosiborod, Mikhail; Butler, Javed; Anker, Stefan D; Mcdonagh, Theresa; Dorobantu, Maria; Drozdz, Jaroslaw; Filippatos, Gerasimos; Nicolau, Jose Carlos
Fonte: European heart journal. Unidade: FM
Assuntos: FERRO, INSUFICIÊNCIA CARDÍACA, FERRO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JANKOWSKA, Ewa A et al. The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European heart journal, v. 42, n. 31, p. 3011-+, 2021Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehab234. Acesso em: 13 jun. 2024.
APA
Jankowska, E. A., Kirwan, B. -A., Kosiborod, M., Butler, J., Anker, S. D., Mcdonagh, T., et al. (2021). The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European heart journal, 42( 31), 3011-+. doi:10.1093/eurheartj/ehab234
NLM
Jankowska EA, Kirwan B-A, Kosiborod M, Butler J, Anker SD, Mcdonagh T, Dorobantu M, Drozdz J, Filippatos G, Nicolau JC. The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study [Internet]. European heart journal. 2021 ; 42( 31): 3011-+.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/eurheartj/ehab234
Vancouver
Jankowska EA, Kirwan B-A, Kosiborod M, Butler J, Anker SD, Mcdonagh T, Dorobantu M, Drozdz J, Filippatos G, Nicolau JC. The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study [Internet]. European heart journal. 2021 ; 42( 31): 3011-+.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/eurheartj/ehab234
Artigo de periodico
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial (2021)
Butt, Jawad H; Nicolau, Jose Carlos ; Verma, Subodh; Docherty, Kieran F; Petrie, Mark C; Inzucchi, Silvio E; Schou, Morten; Kosiborod, Mikhail N; Langkilde, Anna Maria; Martinez, Felipe A
Fonte: European journal of heart failure. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, GLICOSÍDEOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, v. 23, n. 4, p. 601-613, 2021Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2124. Acesso em: 13 jun. 2024.
APA
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., et al. (2021). Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 23( 4), 601-613. doi:10.1002/ejhf.2124
NLM
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.2124
Vancouver
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.2124
Artigo de periodico
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes (2020)
Petrie, Mark C; Verma, Subodh; Docherty, Kieran F; Inzucchi, Silvio E; Anand, Inder; Belohlavek, Jan; Boehm, Michael; Chiang, Chern-En; Chopra, Vijay K.; Nicolau, José Carlos
Fonte: Jama-journal of the american medical association. Unidade: FM
Assuntos: DIABETES MELLITUS, MÉTODO DUPLO-CEGO, HEMOGLOBINAS, INSUFICIÊNCIA CARDÍACA, FÁRMACOS (METABOLISMO E NUTRIÇÃO), PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRIE, Mark C et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, v. 323, n. 14, p. 1353-1368, 2020Tradução . . Disponível em: https://doi.org/10.1001/jama.2020.1906. Acesso em: 13 jun. 2024.
APA
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlavek, J., et al. (2020). Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, 323( 14), 1353-1368. doi:10.1001/jama.2020.1906
NLM
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1001/jama.2020.1906
Vancouver
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1001/jama.2020.1906
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Fonte: Circulation. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 13 jun. 2024.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
Martinez, Felipe A; Serenelli, Matteo; Nicolau, Jose Carlos ; Petrie, Mark C; Chiang, Chern-En; Tereshchenko, Sergey; Solomon, Scott D; Inzucchi, Silvio E; Kober, Lars; Kosiborod, Mikhail N
Fonte: Circulation. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, HIDROCARBONOS AROMÁTICOS, FATORES ETÁRIOS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 13 jun. 2024.
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 13 jun. 2024.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Artigo de periodico
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure (2019)
Ponikowski, Piotr; Kirwan, Bridget-Anne; Anker, Stefan D.; Dorobantu, Maria; Drozdz, Jaroslaw; Fabien, Vincent; Filippatos, Gerasimos; Haboubi, Teba; Keren, Andre; Nicolau, José Carlos
Fonte: European journal of heart failure. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, DOENÇAS NUTRICIONAIS E METABÓLICAS, FERRO, COMPOSTOS INORGÂNICOS, HOSPITALIZAÇÃO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 13 jun. 2024.
APA
Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710
NLM
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.1710
Vancouver
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1002/ejhf.1710
Artigo de periodico
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019)
White, Harvey D; Steg, Ph. Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Erglis, Andrejs; Goodman, Shaun G.; Nicolau, José Carlos
Fonte: European heart journal. Unidade: FM
Assuntos: INFARTO DO MIOCÁRDIO, INSUFICIÊNCIA CARDÍACA, ENZIMAS PROTEOLÍTICAS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WHITE, Harvey D et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, v. 40, n. 33, p. 2801-2809, 2019Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz299. Acesso em: 13 jun. 2024.
APA
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., et al. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, 40( 33), 2801-2809. doi:10.1093/eurheartj/ehz299
NLM
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Vancouver
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Artigo de periodico
Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial (2019)
Nicolau, José Carlos ; Stevens, Susanna R; Al-khalidi, Hussein R; Jatene, Fábio Biscegli ; Furtado, Remo H. M; Dallan, Luís Alberto Oliveira; Lisboa, Luiz A. F; Desvigne-nickens, Patrice; Haddad, Haissam; Jolicoeur, E. Marc
Fonte: International journal of cardiology. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, CIRURGIA, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, José Carlos et al. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International journal of cardiology, v. 291, p. 36-41, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.ijcard.2019.03.029. Acesso em: 13 jun. 2024.
APA
Nicolau, J. C., Stevens, S. R., Al-khalidi, H. R., Jatene, F. B., Furtado, R. H. M., Dallan, L. A. O., et al. (2019). Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International journal of cardiology, 291, 36-41. doi:10.1016/j.ijcard.2019.03.029
NLM
Nicolau JC, Stevens SR, Al-khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-nickens P, Haddad H, Jolicoeur EM. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial [Internet]. International journal of cardiology. 2019 ; 291 36-41.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.ijcard.2019.03.029
Vancouver
Nicolau JC, Stevens SR, Al-khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-nickens P, Haddad H, Jolicoeur EM. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial [Internet]. International journal of cardiology. 2019 ; 291 36-41.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.ijcard.2019.03.029
Artigo de periodico
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019)
Mcmurray, J. J. V; Solomon, S. D; Inzucchi, S. E; Kober, L; Kosiborod, M. N; Martinez, F. A; Ponikowski, P; Sabatine, M. S; Anand, I. S; Nicolau, José Carlos
Fonte: New england journal of medicine. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, PROTEÍNAS DE TRANSPORTE, RESULTADO DE TRATAMENTO, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCMURRAY, J. J. V et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, v. 381, n. 21, p. 1995-2008, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1911303. Acesso em: 13 jun. 2024.
APA
Mcmurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, 381( 21), 1995-2008. doi:10.1056/NEJMoa1911303
NLM
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1056/NEJMoa1911303
Vancouver
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1056/NEJMoa1911303
Trabalho de evento-resumo periodico
Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure (2015)
Issa, V. S.; Lima, G. C.; Ayub-Ferreira, S. M.; Lage, S. G.; Oliveira, M. T.; Nicolau, J.; Bocchi, E. A.
Fonte: Journal of Heart and Lung Transplantation. Nome do evento: Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation. Unidade: FM
Assuntos: ANÁLISE DE COORTE, INSUFICIÊNCIA CARDÍACA, MIOCARDIOPATIA CHAGÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ISSA, V. S. et al. Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure. Journal of Heart and Lung Transplantation. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.healun.2015.01.873. Acesso em: 13 jun. 2024. , 2015
APA
Issa, V. S., Lima, G. C., Ayub-Ferreira, S. M., Lage, S. G., Oliveira, M. T., Nicolau, J., & Bocchi, E. A. (2015). Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure. Journal of Heart and Lung Transplantation. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.healun.2015.01.873
NLM
Issa VS, Lima GC, Ayub-Ferreira SM, Lage SG, Oliveira MT, Nicolau J, Bocchi EA. Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure [Internet]. Journal of Heart and Lung Transplantation. 2015 ; 34( 4S): S310.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.healun.2015.01.873
Vancouver
Issa VS, Lima GC, Ayub-Ferreira SM, Lage SG, Oliveira MT, Nicolau J, Bocchi EA. Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure [Internet]. Journal of Heart and Lung Transplantation. 2015 ; 34( 4S): S310.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.healun.2015.01.873

Unidades USP

ReP

Filtros

Autores

Assuntos

Título da fonte

Agência de fomento